SCHEMBL2810309

SCHEMBL2810309

COCCCOc1cc(CNC2CC2)cc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.47
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41
BACE1 P56817 2/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
MITF O75030 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
OPRK1 P41145 1/20 0.38
TSHR P16473 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13132073 0.85 ALDH1A1 (0.42) ALDH1A1KDM4EPOLBKMT2ACYP2D6
SCHEMBL13132353 0.84 ALDH1A1 (0.54) BCHEACHEBACE1ALDH1A1KDM4E
SCHEMBL13132356 0.82 REN (0.47) RENBCHEACHEBACE1ALDH1A1
SCHEMBL13132072 0.81 KMT2A (0.42) RENBCHEACHEBACE1ALDH1A1
SCHEMBL12525519 0.81 MEN1 (0.50) BCHEACHEBACE1ALDH1A1KDM4E
SCHEMBL13132355 0.81 KDM4E (0.58) RENBACE1ALDH1A1KDM4EKMT2A
SCHEMBL13131326 0.79 REN (0.46) RENCYP1A2SLC6A4HRH1
SCHEMBL13132042 0.79 REN (0.50) RENBCHEACHEBACE1ALDH1A1
SCHEMBL13132071 0.79 POLB (0.42) BCHEACHEBACE1ALDH1A1KDM4E
SCHEMBL13132046 0.79 ALDH1A1 (0.40) RENBCHEACHEBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 REN 1/4885BCHE 1305/4885ACHE 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.